Skip to main content
Medical Science Monitor: International Medical Journal of Experimental and Clinical Research logoLink to Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
. 2015 May 6;21:1297–1303. doi: 10.12659/MSM.893974

MiR-27a Modulates Radiosensitivity of Triple-Negative Breast Cancer (TNBC) Cells by Targeting CDC27

Yong-qiang Ren 1,A,B,C,D,E,F,*, Fengkui Fu 2,A,B,C,D,E,F,*, Jianjun Han 3,A,B,C,D,E,F,G,
PMCID: PMC4548742  PMID: 25943633

Abstract

Background

MiR-27a is significantly overexpressed in triple-negative breast cancer (TNBC). However, the exact biological function of MiR-27a in TNBC is not fully understood. In this study, we verified miR-27a expression in TNBC cells and explored how its overexpression modulates radiosensitivity of the cells.

Material/Method

qRT-PCR analysis was performed to study miR-27a expression in TNBC lines MDA-MB-435 and MDA-MB-231 and in normal human breast epithelial cell line MCF10A. Dual luciferase assay was performed to verify a putative downstream target of miR-27a, CDC27. CCK-8 assay was used to assess the influence of miR-27a-CDC27 axis on cell proliferation under irradiation (IR) treatment.

Results

We confirmed significantly higher miR-27a expression in 2 TNBC cell lines – MDA-MB-435 and MDA-MB-231 – than in human breast epithelial cell line MCF10A. miR-27a could modulate proliferation and radiosensitivity of TNBC cells. CDC-27 is a direct target of miR-27a and its downregulation conferred increased radioresistance of the cells.

Conclusions

The miR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. Testing miR-27a expression might be a useful way to identify a subgroup of patients who will benefit from an IR-based therapeutic approach.

MeSH Keywords: Apc3 Subunit, Anaphase-Promoting Complex-Cyclosome; MicroRNAs; Radiotherapy, Adjuvant; Triple Negative Breast Neoplasms

Background

Triple-negative breast cancer (TNBC), which is defined as the absence of estrogen receptor, progesterone receptor, and HER-2 expression [1], is difficult to treat since most chemotherapies target just 1 of the 3 receptors. Therapies combined with adjuvant radiotherapy help to improve survival of TNBC patients. However, this strategy is challenged due to the emergence of radioresistance of cancer cells [2]. Therefore, understanding the underlying mechanism of radioresistance of TNBC is quite beneficial in developing more effective therapeutic strategy.

miRNAs are a group of small, conservative, non-coding RNAs degrading or repressing the translation of target mRNAs by directly binding to the 3′-UTR [3]. Altered miRNA expression was observed in TNBC and some of the miRNAs play important roles in modulating proliferation, migration, or even radiosensitivity of the cancer cells [4,5]. For example, overexpression of miR-155 in TNBC cancers cells reduces the levels of RAD51, a central protein in homologous recombination modulating cellular response to irradiation (IR) [2]. MiR-31 can directly target protein kinase C Epsilon and thus enhance apoptosis of TNBC cells under IR treatment [6]. MiR-27a is significantly overexpressed in TNBC [7]. In fact, miR-27a has long been recognized as an oncomiR in breast cancer. Its overexpression is associated with endothelial differentiation of breast cancer stem like cells [8]. It can also regulate specificity protein transcription factors and the G2-M checkpoint in TNBC cell line MDA-MB-231 [9], thereby affecting cell proliferation and apoptosis. Since IR induced apoptosis is highly related to cell cycle arrest, miR-27a is highly possible involved in regulation of radiosensitivity of TNBC cells. CDC27 is a core component of anaphase-promoting complex (APC) and is involved in regulation of mitotic checkpoint to ensure chromosomal integrity [10]. Several study observed that APC or CDC27 is downregulated in breast cancer [1113]. However, its upstream regulation in breast cancer is still not clear.

In this study, we verified miR-27a expression in TNBC cells and explored how its overexpression modulates radiosensitivity of the cancer cells.

Material and Methods

Cell culture

Triple negative breast cancer cell line MDA-MB-435 and MDA-MB-231, normal human breast epithelial cell line MCF10A and HEK293T cells were obtained from ATCC. The two breast cancer cells were cultured in RPMI-1640 medium and HEK293T cells were cultured in Dulbecco’s modified Eagle’s (DEME) medium supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 100 μg/mL streptomycin and 100 U/mL penicillin. MCF10A cells were grown in Ham’s F12: DMEM (50:50) medium supplemented with 2 mM L-glutamine, 20 ng/ml epidermal growth factor (EGF) (Sigma), 0.1 mg/ml cholera toxin (CT) (Sigma), 10 mg/ml insulin (Sigma), 500 ng/ml hydrocortisone (Sigma) and 5% horse serum (Atlanta Biologicals). All cells were cultured in an incubator with humidified atmosphere and 5% CO2 at 37°C.

Reagents and cell transfection

MiR-27a mimics, anti-miR-27a (antagomiR-27a), CDC27 siRNA and the negative controls were purchased from RiboBio (China). To overexpress or knockdown or miR-27a, cells were transfected with 75 nM miR-27a mimics or 200nM antagomiR-27a respectively by using lipofectamine 2000 (Invitrogen). To knockdown the expression of CDC27, cells were transfected with 50nM CDC27 siRNA using Oligofectamine (Invitrogen). CDC27 lentiviral expression vectors (without 3′-UTR region) were purchased from GENECHEM (China). To generate adequate lentiviral particles for infection, the lentiviral vectors were transfected to HEK293T cells in combination with the packaging mix. At 48 h after infection, the culture supernatant was collected and the viral titer was determined. To overexpress CDC27, the cells were treated with viral supernatants with the presence of 8 μg/ml Polybrene (Sigma-Aldrich).

Ionizing radiation (IR) (γ-ray)

At 24 h before irradiation treatment, MDA-MB-435 and MDA-MB-231 cells were plated in 25 cm2 polystyrene flasks to form a subconfluent monolayer. Then the cells were irradiated by using a Gamma Cell 40 Exactor (Nordion International) at a dose rate of 2.4 Gy/min.

Quantitative RT-PCR

Total RNAs from MDA-MB-435 and MDA-MB-231 cell samples were extracted with TRIzol reagent (Invitrogen). The absorbance of the RNA samples was determined with a UV-visible spectrophotometer (NanoDrop Technologies) and the samples with A260/A280>2 were used for following studies. Taqman miRNA Assays was used to measure miR-27a expression. RNU6B was used as an internal control. To quantify CDC27 mRNA expression analysis, first strand cDNA was synthesized by using RevertAid first strand cDNA synthesis kit (Fermentas) according to the manufacturer’s instructions. Then qRT-PCR analysis was performed by using Power SYBR Green PCR Master Mix and CDC27 specific primers: (F) 5′-AGAAGTTATGTTGTGGCCTTGG-3′ and (R) 5′-AGGTACAACAGCAGCATGGTTC-3′. All qRT-PCRs were performed with ABI Prism 7300 sequence detection system (Applied Biosystems Inc.).

Western blot analysis of CDC27 protein expression

MDA-MB-435 and MDA-MB-231 cells were lysed with lysis buffer (Beyotime, China). The extract samples were separated by 10% SDS-PAGE gel and then transferred to NC membrane for a conventional Western blotting analysis. The membranes were probed with primary antibodies to CDC27 (1:3000, ab72214, Abcam) and GAPDH (1:2000, ab125247, Abcam) and then incubated with corresponding HRP-conjugated secondary antibody (1:10000, anti-rabbit IgG (HRP) ab191866, Abcam; 1:10000, anti-mouse IgG (HRP), ab6728, Abcam). The signals were visualized by using ECL Western Blotting Substrate (Thermo Scientific Pierce) and the signal intensity was quantified by using Image-J software.

MTT assay of cell proliferation

Cells after different treatments were plated at 5×103 cells/well in 96-well plates. Cells were cultured for 48 h and then cell viability was measured by Cell Counting Kit-8 (CCK-8) (Dojindo) according to manufacturer’s instruction. Each test was performed with 3 repeats.

Flow cytometry analysis of apoptotic cells

At 48 h after treatments, cells were plated in 6-well plates at 4×105 cells/well. The proportion of apoptotic cells was determined by using Fluorescein Active Caspase 3 Staining Kit (88-7004, eBioscience) with a flow cytometry (FACSCalibur, BD Biosciences). The results were analyzed by using ModFit (BD Biosciences).

Dual luciferase analysis

The binding site between miR-27a and CDC27 was predicted by using TargetScan 6.2. With the predication, DNA oligonucleotides with wide-type and mutant sequence of CDC27 3′-UTR were designed and chemically synthesized: WT: forward, 5′-aaacTTACCTGTATTTGTTAGTCAAGCTGTGAAAATAAGGTGGATt-3′; reverse, 5′-ctagaATCCACCTTATTTTCACAGCTTGACTAACAAATACAGGTAAgttt-3′; MUT: forward, 5′-aaac TTACCTGTATTTGTTAGTCAAGGACACTTAATAAGGTGGATt-3′; reverse, 5′-ctagaATCCACCTTATTAAGTGTCCTTGACTAACAAATACAGGTAAgttt-3′. These oligonucleotides were inserted into the downstream of the firefly luciferase gene in pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega) between PmeI and XbaI sites to construct dual luciferase reporters, named as pmirGLO-CDC27-WT and pmirGLO-CDC27-MUT respectively. HEK-293T and MDA-MB-435 cells were co-transfected with 150ng reporter plasmids and 50 nM miR-27a mimics. Both firefly and Renilla luciferase activities were measured 24 h after transfection using the Dual-Luciferase Reporter Assay System (Promega) and the GloMax™ 20/20 Luminometer (Promega).

Statistically analysis

Quantitative variables with normal distribution were reported as median ±SD. Between group comparison was performing using unpaired t-test. p < 0.05 was considered as statistically significant. “*” “**” and “***” donates significance at 0.05, 0.01 and 0.001 level, respectively. All statistical analyses were performed using SPSS for Windows 17.0 (SPSS, Inc).

Results

MiR-27a is significantly increased while CDC27 expression is significantly decreased in TNBC cells

To assess the role of miR-27a in TNBC, TNBC cell line MDA-MB-435 and MDA-MB-231 and normal human breast epithelial cell line MCF10A were used. qRT-PCR analysis showed that miR-27a expression was significantly higher in MDA-MB-435 and MDA-MB-231 cells than in MCF10A cells (Figure 1A). Through preliminary searching and comparison, we identified CDC27 as a highly possible downstream target of miR-27a. Therefore, we also explored the expression of this protein in the cells. In contrast, CDC27 mRNA and protein expression was significantly lower in the 2 cancer cell lines than in the normal cell line (Figure 1B, 1C). These results suggested that miR-27a is significantly associated with TNBC cells, while its expression is negatively correlated with CDC27 expression.

Figure 1.

Figure 1

MiR-27a is significantly increased and CDC27 expression is significantly decreased in TNBC cells. (A) qRT-PCR analysis of miR-27a expression in MDA-MB-435, MDA-MB-231, and MCF10A cell lines. (B) qRT-PCR analysis of CDC27 mRNA expression in MDA-MB-435, MDA-MB-231, and MCF10A cell lines. (C) Western blot analysis of CDC27 expression in MDA-MB-435, MDA-MB-231, and MCF10A cell lines. Data are shown as mean±S.D by 3 independent experiments. * P<0.05, ** P<0.01, *** P<0.001.

MiR-27a is involved in radiosensitivity of TNBC cells

To further explore the biological function of miR-27a, MDA-MB-435 and MDA-MB-231 cells were transfected for miR-27a knockdown (Figure 2A, 2B) and overexpression (Figure 2C, 2D), respectively. In both of the cell lines, miR-27a knockdown significantly inhibited cell proliferation and also enhanced IR-induced proliferation inhibition (Figure 2E, 2F). In contrast, miR-27a overexpression significantly promoted cell proliferation and also alleviated IR-induced proliferation inhibition (Figure 2G, 2H). To further verify the role of miR-27a in radiosensitivity, we assessed how its overexpression and knockdown affect IR induced apoptosis in MDA-MB-435 cells. miR-27a overexpression significantly reduced the proportion of active caspase 3-positive cells, while its knockdown enhanced the apoptosis (Figure 2I, 2J). These results suggest that miR-27a is involved in the regulation of radiosensitivity of TNBC cells.

Figure 2.

Figure 2

MiR-27a is involved in radiosensitivity of TNBC cells. (A–D) qRT-PCR analysis of miR-27a expression in MDA-MB-435 (A, C) MDA-MB-231 (B, D) cells after transfection of 200nM antagomiR-27a (A, B) 75nM miR-27a mimics (C, D). (D–G) CCK-8 assay of cell proliferation of MDA-MB-435 (D, F) MDA-MB-231 (E, G) cells transfected with 200 nM antagomiR-27a with/without treatment of IR (8 Gy) (E, F) or transfected with 75 nM miR-27a mimics with/without treatment of IR (8 Gy) (G, H). (I, J) MDA-MB-435 cells with miR-27a knockdown or overexpression were stained with caspase-3 staining kit 24 h after IR (8 Gy) treatment. Then, flow cytometry analysis was performed to measure the proportion of cells with active caspase-3 staining. Representative flow cytometry images of the cells with active caspase-3 (I). Quantification of apoptotic cells with active caspase-3 signal in Figure 2I, (J). Data are shown as mean ±S.D. by 3 independent experiments. * P<0.05, ** P<0.01, *** P<0.001.

MiR-27a directly targets CDC27 mRNA and regulates its expression in TNBC cells

Although the regulative role of miR-27a in TNBC cells has been verified, its downstream targets are still not clear. Through searching and comparison in online bioinformatics databases, we found CDC27 has a highly conserved 3′UTR sequence with miR-27a in mammals (Figure 3A). Then, we verified this binding using dual-luciferase assay in both HEK-293T and MDA-MB-435 cells. In both of these 2 cell lines, miR-27a mimics could only inhibit luciferase activity of reporters carrying the wide-type binding sites, but had no effect on the mutant reporter (Figure 3B, 3C). MDA-MB-435 cells transfected with miR-27a mimics had significantly reduced CDC27 expression at protein level, while the cells transfected with antagomiR-27a had significantly enhanced CDC27 expression (Figure 3D, 3E). These results suggest that miR-27a can directly target CDC27 and regulate its expression in TNBC cells.

Figure 3.

Figure 3

MiR-27a directly targets CDC27 and regulates its expression in TNBC cells. (A) The putative binding site between miR-27a and CDC27 and the designed mutant sequence without the pairing. (B, C) The relative firefly luciferase activity in HEK-293T (B) and MDA-MB-435 (C) cells co-transfected with 150 ng reporter plasmids and 50 nM miR-27a mimics. Both firefly and Renilla luciferase activities were measured 24 h after transfection and the firefly luciferase activity was normalized to the Renilla luciferase activity. (D, E) Western blot analysis of CDC27 protein expression in MDA-MB-435 transfected with miR-27a mimics or siCDC-27 (D) or transfected with antagomiR-27a or infected with CDC-27 lentiviral particles (E). Data are shown as mean ±S.D. by 3 independent experiments. * P<0.05, ** P<0.01, *** P<0.001.

MiR-27a modulates radiosensitivity of TNBC cells through targeting CDC27

Because the regulative role of miR-27a on CDC27 was verified in TNBC cells, we further studied whether this axis is involved in regulation of radiosensitivity. Transfection of CDC27 in both MDA-MB-435 and MDA-MB-231 cells could inhibit cell proliferation. In addition, CDC27 overexpression also enhanced IR-induced inhibition of cell growth (Figure 4A, 4B). At the same time, knockdown of CDC27 in these 2 cell lines conferred increased cell growth, with or without IR treatment (Figure 4C, 4D). Transfection of CDC27 could significantly abrogate miR-27a-induced growth promotion (Figure 4E, 4F). However, knockdown of CDC27 could rescue cell growth inhibition induced by miR-27a knockdown (Figure 4G, 4H). These results suggest that miR-27a can modulate radiosensitivity of TNBC cells through targeting CDC27.

Figure 4.

Figure 4

MiR-27a modulates radiosensitivity of TNBC cells through targeting CDC27. (A–D) CCK-8 assay of cell proliferation in MDA-MB-435 (A, C) MDA-MB-231 (B, D) cells after infection with CDC27 lentiviral particle with/without treatment of IR (8 Gy) (A, B) or transfected with 50 nM siCDC27 with/without treatment of IR (8 Gy) (C, D). (E, F) The effect of co-transfection of miR-27a and CDC27 on cell proliferation in MDA-MB-435 (E) MDA-MB-231 (F) cells with/without treatment of IR (8 Gy). (G, H) The effect of co-transfection of antagomiR-27a and siCDC27 on cell proliferation in MDA-MB-435 (G) MDA-MB-231 (H) cells with/without treatment of IR (8 Gy). Data are shown as mean ±S.D. by 3 independent experiments. * P<0.05, ** P<0.01, *** P<0.001.

Discussion

MiR-27a is one the miRNAs significantly upregulated in TNBC patients [7]; its high expression is associated with poor overall patient survival [14]. Its oncogenic mechanisms have been widely reported in breast cancer. miR-27a can directly target FOXO1 and thus regulate transformation or maintenance of an oncogenic state in breast cancer cells [15]. It can also regulate specificity protein transcription factors and the G2-M checkpoint in TNBC cells MDA-MB-231 [9], thereby affecting cell proliferation and apoptosis. However, since a miRNA usually has multiple targets and the targets may vary in different pathological process, how miR-27a affects TNBC needs to be further studied. In the current study, we confirmed significantly higher miR-27a expression in 2 TNBC cell lines – MDA-MB-435 and MDA-MB-231 – than in normal human breast epithelial cell line MCF10A. In addition, we also observed that miR-27a could modulate proliferation and radiosensitivity of TNBC cells. However, the exact mechanism is not clear.

CDC27 is a core component of the anaphase-promoting complex (APC) and is involved in regulation of mitotic checkpoints to ensure chromosomal integrity [10]. APC plays a critical role in promoting metaphase-anaphase transition through ubiquitizing and degrading securin. It also promotes the M-to-G1 transition by ubiquitinating cyclin-B and accelerating its degradation [16]. Therefore, as a core component of APC, dysregulation of CDC27 may significantly affect the function of the polymeric protein complex. Due to its importance in mitotic checkpoints or spindle assembly checkpoint (SAC) control, this molecule is considered as a target of some anticancer drug [17]. It has been reported that APC or CDC27 is downregulated in breast cancer [11]. However, how it is dysregulated and the exact biophysical function of this protein in breast cancer is not fully understood.

In this study, we verified a highly conserved putative binding site between miR-27a and CDC27 and demonstrated that miR-27a can directly regulate CDC27 expression in TNBC cancer cells. There is emerging evidence showing that TNBC cells are characterized by altered distribution of cell cycles, checkpoints of chromosomal integrity, and control of DNA damage repair [18,19]. A recent study reported that lower expression of protein predicted shorter survival time for breast cancer patients [11]. Therefore, it might act as a tumor suppressor in breast cancer. Due to the important role of CDC27/APC in the mitotic regulatory pathway, it might also be involved in regulation of IR-induced cell death. A previous study reported that lower expression CDC27 was associated with poorer response to radiotherapy in squamous cell cervix carcinoma [20]. In the current study, we explored the role of CDC27 in regulation of radiosensitivity of TNBC cells and found its downregulation conferred increased radioresistance of the cells. Therefore, the miR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. In fact, radiosensitivity might be regulated by a complex network. For example, overexpression of miR-155 in human breast cancer cells can reduce RAD51 expression, a central protein in homologous recombination, thereby affecting the cellular response to IR [2]. MiR-31 can also enhance apoptosis of TNBC cells under IR treatment [6]. More studies are required to explore the underlying mechanism of radioresistance in TNBC.

Conclusions

The MiR-27a-CDC27 axis might play an important role in modulating response to radiotherapy in TNBC cells. Testing miR-27a expression might be a useful practice to a identify subgroup of patients who will benefit from an IR-based therapeutic approach.

Footnotes

Source of support: Departmental sources

References

  • 1.Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938–48. doi: 10.1056/NEJMra1001389. [DOI] [PubMed] [Google Scholar]
  • 2.Gasparini P, Lovat F, Fassan M, et al. Protective role of mir-155 in breast cancer through rad51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci USA. 2014;111:4536–41. doi: 10.1073/pnas.1402604111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bartel DP. Micrornas: Genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97. doi: 10.1016/s0092-8674(04)00045-5. [DOI] [PubMed] [Google Scholar]
  • 4.Yahya SM, Elsayed GH. A summary for molecular regulations of mirnas in breast cancer. Clin Biochem. 2015;48(6):388–96. doi: 10.1016/j.clinbiochem.2014.12.013. [DOI] [PubMed] [Google Scholar]
  • 5.Min W, Wang B, Li J, et al. The expression and significance of five types of mirnas in breast cancer. Med Sci Monit Basic Res. 2014;20:97–104. doi: 10.12659/MSMBR.891246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Korner C, Keklikoglou I, Bender C, et al. Microrna-31 sensitizes human breast cells to apoptosis by direct targeting of protein kinase c epsilon (pkcepsilon) J Biol Chem. 2013;288:8750–61. doi: 10.1074/jbc.M112.414128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gasparini P, Cascione L, Fassan M, et al. Microrna expression profiling identifies a four microrna signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget. 2014;5:1174–84. doi: 10.18632/oncotarget.1682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Tang W, Yu F, Yao H, et al. Mir-27a regulates endothelial differentiation of breast cancer stem like cells. Oncogene. 2014;33:2629–38. doi: 10.1038/onc.2013.214. [DOI] [PubMed] [Google Scholar]
  • 9.Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microrna-27a targets genes that regulate specificity protein transcription factors and the g2-m checkpoint in mda-mb-231 breast cancer cells. Cancer Res. 2007;67:11001–11. doi: 10.1158/0008-5472.CAN-07-2416. [DOI] [PubMed] [Google Scholar]
  • 10.Thornton BR, Ng TM, Matyskiela ME, et al. An architectural map of the anaphase-promoting complex. Genes Dev. 2006;20:449–60. doi: 10.1101/gad.1396906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Talvinen K, Karra H, Pitkanen R, et al. Low cdc27 and high securin expression predict short survival for breast cancer patients. APMIS. 2013;121:945–53. doi: 10.1111/apm.12110. [DOI] [PubMed] [Google Scholar]
  • 12.Singh N, Wiltshire TD, Thompson JR, et al. Molecular basis for the association of microcephalin (mcph1) protein with the cell division cycle protein 27 (cdc27) subunit of the anaphase-promoting complex. J Biol Chem. 2012;287:2854–62. doi: 10.1074/jbc.M111.307868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Stevens KN, Wang X, Fredericksen Z, et al. Evaluation of associations between common variation in mitotic regulatory pathways and risk of overall and high grade breast cancer. Breast Cancer Res Treat. 2011;129:617–22. doi: 10.1007/s10549-011-1587-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Tang W, Zhu J, Su S, et al. Mir-27 as a prognostic marker for breast cancer progression and patient survival. PloS One. 2012;7:e51702. doi: 10.1371/journal.pone.0051702. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Guttilla IK, White BA. Coordinate regulation of foxo1 by mir-27a, mir-96, and mir-182 in breast cancer cells. J Biol Chem. 2009;284:23204–16. doi: 10.1074/jbc.M109.031427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chang L, Zhang Z, Yang J, et al. Molecular architecture and mechanism of the anaphase-promoting complex. Nature. 2014;513:388–93. doi: 10.1038/nature13543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lee SJ, Langhans SA. Anaphase-promoting complex/cyclosome protein cdc27 is a target for curcumin-induced cell cycle arrest and apoptosis. BMC Cancer. 2012;12:44. doi: 10.1186/1471-2407-12-44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ha G, Roth A, Lai D, et al. Integrative analysis of genome-wide loss of heterozygosity and monoallelic expression at nucleotide resolution reveals disrupted pathways in triple-negative breast cancer. Genome Res. 2012;22:1995–2007. doi: 10.1101/gr.137570.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Yang L, Perez AA, Fujie S, et al. Wnt modulates mcl1 to control cell survival in triple negative breast cancer. BMC Cancer. 2014;14:124. doi: 10.1186/1471-2407-14-124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rajkumar T, Gopal G, Selvaluxmi G, Rajalekshmy KR. Cdc27 protein is involved in radiation response in squamous cell cervix carcinoma. Indian J Biochem Biophys. 2005;42:271–78. [PubMed] [Google Scholar]

Articles from Medical Science Monitor : International Medical Journal of Experimental and Clinical Research are provided here courtesy of International Scientific Information, Inc.

RESOURCES